Direct and indirect costs of women diagnosed with menopause symptoms

Journal of Occupational and Environmental Medicine

Volumn 55, Issue 4, 2013, Pages 465-470

  Kleinman, Nathan L ^a   Rohrbacker, Nicholas J ^a,b   Bushmakin, Andrew G ^c   Whiteley, Jennifer ^c   Lynch, Wendy D ^a   Shah, Sonali N ^c  

^a Human Capital Management Services   (United States)

^b Wellpoint Inc   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; HYPNOTIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ABSENTEEISM; ACUPUNCTURE; ADULT; AGED; ANXIETY; ARTICLE; CHIROPRACTIC; CONTROLLED STUDY; COST OF ILLNESS; DRUG COST; EMPLOYEE; FEMALE; HEALTH CARE COST; HIP FRACTURE; HUMAN; HYSTERECTOMY; INSOMNIA; INVOLUTIONAL DEPRESSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MEDICAL LEAVE; MENOPAUSAL SYNDROME; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRODUCTIVITY; SALARY; SPINE FRACTURE; WORK DISABILITY; WORKMAN COMPENSATION;

ADULT; AGED; COMORBIDITY; COST OF ILLNESS; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; MENOPAUSE; MIDDLE AGED; REGRESSION ANALYSIS; SICK LEAVE; UNITED STATES;

EID: 84876409034     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3182820515     Document Type: Article

References (30)

1. United States Department of Labor. Bureau of Labor Statistics Current Population Survey. Available at: http://data.bls.gov/pdq/querytool.jsp?survey= ln. Accessed May 9, 2011.
2. Umland EM. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms. J Manag Care Pharm. 2008;14:S14-S19.
3. Berecki-Gisolf J, Begum N, Dobson AJ. Symptoms reported by women in midlife: menopausal transition or aging? Menopause. 2009;16:1021-1029.
4. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consensus State-of-the-Science Statements. 2005. 21-23;22:1-38.
5. Keenan NL, Mark S, Fugh-Berman A, et al. Severity of menopausal symptoms and use of both conventional and complementary/alternative therapies. Menopause. 2003;10:507-515.
6. Reed SD, Ludman EJ, Newton KM, et al. Depressive symptoms and menopausal burden in the midlife. Maturitas. 2009;62:306-310.
7. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63:375-382.
8. Joffe H, Hall JE, Soares CN, et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause. 2002;9:392-398.
9. Williams RE, Kalilani L, DiBenedetti DB, et al. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007;58:348-358.
10. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005;3:47.
11. Feldman BM, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health. 1985;8:261-268.
12. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52-86.
13. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
14. Buist DSM, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004;104:1042-1050.
15. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
16. Newton KM, Buist DSM, Keenan NL, et al. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol. 2002;100:18-25.
17. Gold EB, Bair Y, Zhang G, et al. Cross-sectional analysis of specific complementary and alternative medicine (CAM) use by racial/ethnic group and menopausal status: the Study of Women's Health Across the Nation (SWAN). Menopause. 2007;14:612-623.
18. Pinkerton JV, Stovall DW, Kightlinger RS. Advances in the treatment of menopausal symptoms. Women's Health. 2009;5:361-384.
19. Botteman MF, Shah NP, Lian J, et al. A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms. Menopause. 2004;11: 343-355.
20. Kjerulff KH, Frick KD, Rhoades JA, Hollenbeak CS. The cost of being a woman: a national study of health care utilization and expenditures for female-specific conditions. Womens Health Issues. 2007;17:13-21.
21. Williams RE, Levine KB, Kalilani L, et al. Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas. 2009;62:153-159.
22. Bolge SC, Balkrishnan R, Kannan H, et al. Burden associated with chronic sleep maintenance insomnia characterized by nighttime awakenings among women with menopausal symptoms. Menopause. 2010;17:80-86.
23. Chedraui P, San Miguel G, Avila C. Quality of life impairment during the female menopausal transition is related to personal and partner factors. Gynecol Endocrinol. 2009;25:130-135.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
25. United States Department of Labor. Consumer price indices for medical services, prescription drugs, and all consumer goods. Available at: http://data. bls.gov/PDQ/outside.jsp?survey=cu. Accessed April 1, 2011.
26. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
27. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-427.
28. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477.
29. AACE Menopause Guidelines Revision Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract. 2006;12: 315-337.
30. The North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 2004;11:11-33.